Cargando…

Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy

PURPOSE: Infiltration of tumor associated lymphocytes and count of its different phenotypes are potentially new independent predictor of prognosis in breast cancer. However, research related to it is less reported in breast cancer patients treated with anti-Her-2 therapy. Thus, we evaluated the rela...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Tan-Huan, Zhang, Ying-Chun, Tan, Yu-Ting, An, Xin, Xue, Cong, Deng, Ying-Fei, Yang, Wei, Yuan, Xia, Shi, Yan-Xia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354903/ https://www.ncbi.nlm.nih.gov/pubmed/28029650 http://dx.doi.org/10.18632/oncotarget.14124

Ejemplares similares

Clinical characteristics, tumor‐infiltrating lymphocytes, and prognosis in HER2‐low breast cancer: A comparison study with HER2‐zero and HER2‐positive disease
por: Lu, Yujie, et al.
Publicado: (2023)

Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
por: Yang, Xia, et al.
Publicado: (2018)

The types of tumor infiltrating lymphocytes are valuable for the diagnosis and prognosis of breast cancer
por: Sun, Ying, et al.
Publicado: (2022)

Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes
por: Liu, Shiwei, et al.
Publicado: (2020)

Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
por: Luque, Melani, et al.
Publicado: (2022)

Tumor-infiltrating lymphocyte: features and prognosis of lymphocytes infiltration on colorectal cancer
por: Qin, Miao, et al.
Publicado: (2023)

Prognostic and predictive role of spatially positioned tumour infiltrating lymphocytes in metastatic HER2 positive breast cancer treated with trastuzumab
por: Honkanen, Tiia J., et al.
Publicado: (2017)

Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis
por: Li, Shiqi, et al.
Publicado: (2022)

The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer
por: Eustace, A. J., et al.
Publicado: (2021)

Prognostic Value of Tumor Infiltrating Lymphocytes in Locally Advanced HER2 Enriched Breast Cancer
por: Saber, Mostafa M, et al.
Publicado: (2022)

Lymphocyte-activating gene-3 expression is associated with tumor-infiltrating lymphocyte levels in HER2-positive breast cancers
por: Lee, Seokwon, et al.
Publicado: (2021)

A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab
por: Hong, Jin, et al.
Publicado: (2019)

Effects of tumor-infiltrating lymphocytes on nonresponse rate of neoadjuvant chemotherapy in patients with invasive breast cancer
por: Qian, Xiao-Long, et al.
Publicado: (2023)

Vulval superficial myofibroblastoma with lymphocytic and eosinophilic infiltrate
por: Tan, Qi Ting, et al.
Publicado: (2023)

Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients
por: Schirosi, Laura, et al.
Publicado: (2019)

The ratio of intratumour to stromal infiltrating lymphocytes better predicts prognosis in breast cancer
por: Zhang, Baoyi, et al.
Publicado: (2023)

Low Expression of PLAT in Breast Cancer Infers Poor Prognosis and High Immune Infiltrating Level
por: Wang, Xinyang, et al.
Publicado: (2021)

ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy
por: Ma, Fei, et al.
Publicado: (2016)

A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
por: Hamy, Anne-Sophie, et al.
Publicado: (2016)

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
por: Hida, Akira I., et al.
Publicado: (2016)

The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression
por: Shang, Mao, et al.
Publicado: (2022)

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
por: Dieci, M V, et al.
Publicado: (2019)

Tumour-infiltrating lymphocytes: from prognosis to treatment selection
por: Brummel, Koen, et al.
Publicado: (2022)

Association of tumor‐infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer
por: Hong, Jin, et al.
Publicado: (2021)

Tumor budding and tumor‐infiltrating lymphocytes can predict prognosis in pT1b esophageal squamous cell carcinoma
por: Li, Zhuo, et al.
Publicado: (2023)

Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Grandal, Beatriz, et al.
Publicado: (2020)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
por: Shao, Bin, et al.
Publicado: (2022)

CD47 and CD68 expression in breast cancer is associated with tumor‐infiltrating lymphocytes, blood vessel invasion, detection mode, and prognosis
por: Chen, Ying, et al.
Publicado: (2023)

Tumor high endothelial venules (HEVs) predict lymphocyte infiltration and favorable prognosis in breast cancer
por: Martinet, Ludovic, et al.
Publicado: (2012)

FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis
por: TAKENAKA, MIKI, et al.
Publicado: (2013)

No Impact of Smoking Status on Breast Cancer Tumor Infiltrating Lymphocytes, Response to Neoadjuvant Chemotherapy and Prognosis
por: Simon, Vanille, et al.
Publicado: (2020)

Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

FN1 overexpression is correlated with unfavorable prognosis and immune infiltrates in breast cancer
por: Zhang, Xiu-Xia, et al.
Publicado: (2022)

BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy
por: Kim, Sung-Bae, et al.
Publicado: (2019)

Prognosis of tumor infiltrating lymphocytes in operable tongue cancer patients
por: Chen, Wan-Yu, et al.
Publicado: (2014)

Synergistic association of FOXP3(+) tumor infiltrating lymphocytes with CCL20 expressions with poor prognosis of primary breast cancer: A retrospective cohort study
por: Zhao, Xia, et al.
Publicado: (2019)

Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer
por: Huertas-Caro, Carlos A., et al.
Publicado: (2023)

Relevance of tumor-infiltrating lymphocytes in breast cancer
por: Dushyanthen, Sathana, et al.
Publicado: (2015)

The Possible Role of Anti- and Protumor-Infiltrating Lymphocytes in Pathologic Complete Response in Early Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy
por: Geršak, Klara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_26cvt60p8ifa2punohhhcuo6dq